GTHX stock icon

G1 Therapeutics
GTHX

$2.20
2.25%
 

About: G1 Therapeutics Inc is a commercial-stage biopharmaceutical company. It is engaged in developing novel, small-molecule therapies to target unmet needs in the treatment of cancer. The firm is developing drugs that have the potential to treat the types of cancer, such as cell lung cancer and breast cancer, and designs them to combine and enhance the anti-tumor activity of current therapies. Its product COSELA indicates to help protect bone marrow from the damage of chemotherapy.

Employees: 100

0
Funds holding %
of 6,702 funds
0
Analysts bullish %
of 14 analysts
0
News positive %
of 7 articles

Fund manager confidence

Based on 2024 Q1 SEC filings by fund managers ($100M+ AUM)

140% more call options, than puts

Call options by funds: $4.23M | Put options by funds: $1.76M

100% more repeat investments, than reductions

Existing positions increased: 32 | Existing positions reduced: 16

60% more capital invested

Capital invested by funds: $38.5M [Q4 2023] → $61.6M (+$23.1M) [Q1 2024]

3.06% more ownership

Funds ownership: 24.34% [Q4 2023] → 27.41% (+3.06%) [Q1 2024]

0% more funds holding

Funds holding: 86 [Q4 2023] → 86 (+0) [Q1 2024]

0% more first-time investments, than exits

New positions opened: 18 | Existing positions closed: 18

Research analyst outlook

14 Wall Street Analysts provided 1 year price forecasts over the past 6 months

Low target
$3
36%
upside
Avg. target
$9.86
348%
upside
High target
$14
536%
upside

14 analyst ratings

14 positive
100%
neutral
0%
negative
0%
HC Wainwright & Co.
Edward White
36%upside
$3
Buy
Maintained
25 Jun 2024
Needham
Gil Blum
173%upside
$6
Buy
Maintained
25 Jun 2024
Needham
Gil Blum
445%upside
$12
Buy
Reiterated
13 Jun 2024
HC Wainwright & Co.
Edward White
309%upside
$9
Buy
Reiterated
28 May 2024
Needham
Gil Blum
445%upside
$12
Buy
Reiterated
28 May 2024

Financial journalist opinion

Based on 7 articles about GTHX published over the past 30 days